spa-s-132 and Candidiasis

spa-s-132 has been researched along with Candidiasis* in 1 studies

Other Studies

1 other study(ies) available for spa-s-132 and Candidiasis

ArticleYear
Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis.
    The Journal of antimicrobial chemotherapy, 2001, Volume: 47, Issue:2

    The polyene partricin compound SPA-S-753 (Societa Prodotti Antibiotici, Milano, Italy) was assessed in a murine model of systemic candidosis. CD-1 mice were infected iv with Candida albicans and treated iv with SPA-S-753 or amphotericin B. All treatment regimens of SPA-S-753 or amphotericin B were equivalent and significantly prolonged survival compared with controls (P < 0.001). Amphotericin B and SPA-S-753 significantly reduced burdens of C. albicans in the spleen and kidneys. Overall, cure rates were similar, amphotericin B at 1 mg/kg cured three and SPA-S-753 at 10 mg/kg cured four mice of infection in both organs. The efficacy of SPA-S-753 is between equivalent and <10-fold as potent as amphotericin B. These results are encouraging and warrant further studies on SPA-S-753.

    Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Injections, Intravenous; Kidney; Mice; Microbial Sensitivity Tests; Polyenes; Spleen

2001